Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
Date:7/30/2013

THE WOODLANDS, Texas, July 30, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2013.

"We have continued to advance multiple programs in our clinical pipeline, most notably completing enrollment of Phase 2 studies of telotristat etiprate in ulcerative colitis and LX1033 in diarrhea-predominant irritable bowel syndrome. We look forward to obtaining top-line results from these studies around the end of the third quarter and in the fourth quarter of 2013, respectively," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "In addition, we obtained initial safety data from the pioneer portion of our Phase 2 trial of LX4211 in Type 1 diabetes and subsequently advanced the study into its expansion phase."Progress in Clinical Pipeline

  • LX4211:  LX4211 is a dual inhibitor of sodium-glucose transporters 1 and 2 (SGLT1 and SGLT2).  SGLT1 is primarily responsible for glucose absorption in the gastrointestinal tract and SGLT2 is responsible for most of the glucose reabsorption performed by the kidney.  At the 73rd Scientific Sessions of the American Diabetes Association, Lexicon presented a sub-analysis of blood pressure effects observed in the 12-week dose-ranging Phase 2b study of LX4211 in type 2 diabetes.  Notably, patients with high baseline systolic blood pressure (≥130 mmHg) dosed with LX4211 experienced an average of 14 mmHg reduction in systolic blood pressure when compar
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Lexicon to Report Second Quarter Financial Results on July 30, 2013
    2. Lexicon Presents Data at the American Diabetes Association Meeting On Blood Pressure Reduction and Weight Loss In Clinical Trial of LX4211
    3. Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
    4. Lexicon To Present At The Goldman Sachs Global Healthcare Conference
    5. Lexicon To Present At The Jefferies Global Healthcare Conference
    6. Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
    7. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results
    8. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
    9. Lexicon to Report First Quarter Financial Results on May 10, 2013
    10. Lexicon To Present At The Needham Healthcare Conference
    11. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... Research and Markets has announced the addition ... report to their offering. Multiple ... in demyelination, axonal transection, and neurodegeneration. The myelin sheath ... immune system, which targets neurons within the central nervous ... which the damage of the myelin sheath causes disruption ...
    (Date:8/29/2014)... Aug. 29, 2014  Pacific Medical Data Solutions is ... website design . The main website, along with the ... company,s new services and content relevant to the medical ... streamlined design, viewers can now better understand how PMDS ... practices and create a more visible platform about medical ...
    (Date:8/29/2014)... , Aug. 29, 2014 Research and ... Orthopedic Soft Tissue Repair Devices Market 2014-2018" report ... are the mass of cells that connect, support, or ... tissues such as tendons, ligaments, cartilage, fascia, and other ... of these tissues with age result in wear and ...
    Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3PMDS Announces New Website 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
    ... 2011 Brain Plasticity Inc. (BPI), a technology incubator ... that harness the basic principles of brain plasticity to ... disorders, was recently awarded a $2 million grant from ... The grant will fund a two-year clinical trial of ...
    ... recent paper published in the Journal of Glaucoma ... a fast, objective method to screen for functional damage in ... significantly decreases test duration and provides less subjectivity in evaluating ... out at New York Eye and Ear Infirmary (New York, ...
    Cached Medicine Technology:U.S. Department of Defense Awards $2 Million to Brain Plasticity Inc. to Study Impact of Brain Training for Traumatic Brain Injuries 2U.S. Department of Defense Awards $2 Million to Brain Plasticity Inc. to Study Impact of Brain Training for Traumatic Brain Injuries 3New Test to Screen for Glaucoma Damage 2
    (Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- Astronauts ... travel appears to disrupt human immune systems, a new ... on any long missions to asteroids, the moon and ... or flu while in space can be dangerous, NASA ... immune cells in the blood of International Space Station ...
    (Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- If you have ... more serious treatment later, an expert says. A bunion ... big toe when bone or tissue moves out of place ... untreated, bunions can cause debilitating pain and may require surgery ... at CentraState Medical Center in Freehold, N.J. To prevent ...
    (Date:8/29/2014)... IL (PRWEB) August 29, 2014 A ... hearing wellness solutions, is on its way to the ... the San Diego Convention Center to exhibit and demonstrate ... work in high-noise industrial environments. Etymotic’s safety earphones and ... wearable technology devices at the show. , The ...
    (Date:8/29/2014)... 2014 LiveOps, Inc., the global leader ... announced that LiveOps has been selected as a call ... of Strength Telethon for the third year in a ... awareness to support MDA’s mission to help children and ... fatal muscle disease. This year’s program includes performances by ...
    (Date:8/29/2014)... cancer patients lacking knowledge about the disease have difficulty ... quality of care and long-term results, new research suggests. ... age of 63. All were newly diagnosed with localized ... associated with greater difficulty deciding which treatment to choose ... the study found. "For prostate cancer, there is ...
    Breaking Medicine News(10 mins):Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2Health News:Take Steps to Control Bunions 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 3Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 4Health News:Faced With Prostate Cancer, It Helps to Know the Enemy 2
    ... ... with AiRISTA to provide Wi-Fi-based RFID solutions. , ... Sparks, Maryland (PRWEB) September 14, 2009 ... (DCC) to promote, distribute, implement and support AiRISTA,s solutions and technologies ( www.AiRISTA.com ...
    ... works in different way than standard medicines , SUNDAY, ... people whose high blood pressure cannot be controlled by ... researchers report. , Substantial reductions in blood pressure were ... people who were still hypertensive despite trying three or ...
    ... ... has been awarded the prestigious Gold certification from Cisco systems for ... The Certification recognizes High Point,s expert level of achievement for advanced ... Data Center. Gold Certified Partners are considered extensions of Cisco,s support ...
    ... the first ever found to prevent cartilage loss from osteoarthritis ... cartilage that has been lost to osteoarthritis, according to an ... American Society for Bone and Mineral Research in Denver. While ... osteoarthritis that develops following knee injuries, according to the study ...
    ... say they,ll donate than do, leaving long waits for transplants ... and large say they support the idea of donating some ... lives, reality presents a different picture. , Just 38 percent ... organ and tissue donors, according to a report this year ...
    ... , FRAMINGHAM, Mass., Sept. 11 Philips Lifeline ... subscribers of its personal emergency response service to alert users of ... is used primarily by seniors living independently in their homes who ... button" worn on the body, users connect to a remote monitoring ...
    Cached Medicine News:Health News:AiRISTA's Unified Visibility Solutions Bringing Together Wi-Fi RTLS, And Telemetry Offer Enormous Business Opportunities To Systems Integrators 2Health News:Drug Offers Hope Against Tough-to-Treat Hypertension 2Health News:Drug Offers Hope Against Tough-to-Treat Hypertension 3Health News:High Point Solutions has Been Awarded the Prestigious Gold Certification from Cisco Systems 2Health News:Hormone promises to keep joint injuries from causing long-term osteoarthritis 2Health News:Hormone promises to keep joint injuries from causing long-term osteoarthritis 3Health News:Hormone promises to keep joint injuries from causing long-term osteoarthritis 4Health News:For Organ Donation, Intent and Reality Don't Align 2Health News:For Organ Donation, Intent and Reality Don't Align 3Health News:Lifeline Issues Safety Notice to Subscribers 2
    Skin Tone External Eyelid Weights...
    To prevent retraction of the conjunctival cul-de-sacs without touching the cornea....
    Bioceramic orbital implants insert easily into orbital socket and will not cling to surrounding tissue. Improved interconnectivity between pores enhances vascularization. Implants may be easily drill...
    ...
    Medicine Products: